Eyenovia Stock Today

EYEN Stock  USD 1.07  0.07  7.00%   

Performance

12 of 100

 
Weak
 
Strong
Good

Odds Of Distress

Over 69

 
High
 
Low
Quite High
Eyenovia is selling at 1.07 as of the 15th of July 2024; that is 7.00 percent increase since the beginning of the trading day. The stock's open price was 1.0. Eyenovia has more than 69 % chance of experiencing financial distress in the next few years of operation. However, it had a very good returns during the last 90 days. Equity ratings for Eyenovia are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 15th of June 2024 and ending today, the 15th of July 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
25th of January 2018
Category
Healthcare
Classification
Health Care
Eyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print platform technology. Eyenovia, Inc. was incorporated in 2014 and is headquartered in New York, New York. Eyenovia operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 61.45 M outstanding shares of which 3.93 M shares are currently shorted by private and institutional investors with about 6.15 trading days to cover. More on Eyenovia

Moving together with Eyenovia Stock

  0.66DMAC DiaMedica TherapeuticsPairCorr

Moving against Eyenovia Stock

  0.51DOMH Dominari HoldingsPairCorr
  0.51DRUG Bright Minds BiosciencesPairCorr
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Eyenovia Stock Highlights

Business ConcentrationPharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover1.0E-42.0E-4
Sufficiently Down
Very volatile
Total Current Liabilities6.2 M9.5 M
Way Down
Slightly volatile
Total Assets21 M28.8 M
Way Down
Slightly volatile
Total Current Assets17.7 M16.4 M
Significantly Up
Slightly volatile
Debt Levels
Eyenovia can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Eyenovia's financial leverage. It provides some insight into what part of Eyenovia's total assets is financed by creditors.
Liquidity
Eyenovia currently holds 16.11 M in liabilities with Debt to Equity (D/E) ratio of 0.31, which is about average as compared to similar companies. Eyenovia has a current ratio of 2.1, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Eyenovia's use of debt, we should always consider it together with its cash and equity.

Total Cashflows From Investing Activities

(1.38 Million)
Eyenovia (EYEN) is traded on NASDAQ Exchange in USA. It is located in 295 Madison Avenue, New York, NY, United States, 10017 and employs 57 people. Eyenovia is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 65.75 M. Eyenovia conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 61.45 M outstanding shares of which 3.93 M shares are currently shorted by private and institutional investors with about 6.15 trading days to cover. Eyenovia currently holds about 21.51 M in cash with (23.84 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.63.
Check Eyenovia Probability Of Bankruptcy
Ownership Allocation
Eyenovia shows 15.85 percent of its outstanding shares held by insiders and 14.455 percent owned by other corporate entities.
Check Eyenovia Ownership Details

Eyenovia Stock Institutional Holders

InstituionRecorded OnShares
Jane Street Group, Llc2023-12-31
91.4 K
Charles Schwab Investment Management Inc2024-03-31
75.9 K
Bank Of New York Mellon Corp2024-03-31
74.7 K
Millennium Management Llc2024-03-31
72.2 K
Pfg Investments, Llc2024-03-31
70 K
Xtx Topco Ltd2024-03-31
65.3 K
Ubs Group Ag2024-03-31
45.3 K
Sei Investments Co2024-03-31
43.7 K
Nations Financial Group Inc2024-03-31
40.9 K
Vanguard Group Inc2024-03-31
1.8 M
Blackrock Inc2024-03-31
1.6 M
View Eyenovia Diagnostics

Eyenovia Historical Income Statement

At this time, Eyenovia's Interest Income is very stable compared to the past year. As of the 15th of July 2024, Depreciation And Amortization is likely to grow to about 822.4 K, while Selling General Administrative is likely to drop about 7.3 M. View More Fundamentals

Eyenovia Stock Against Markets

Eyenovia Corporate Management

Bren KernVP OperationsProfile
Michael RoweCEO DirectorProfile
Alexander LoboInvestor ContactProfile
MD MPHPresident, CoFounderProfile

Additional Information and Resources on Investing in Eyenovia Stock

When determining whether Eyenovia offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Eyenovia's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Eyenovia Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Eyenovia Stock:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eyenovia. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.
To learn how to invest in Eyenovia Stock, please use our How to Invest in Eyenovia guide.
You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eyenovia. If investors know Eyenovia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eyenovia listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.74)
Quarterly Revenue Growth
4
Return On Assets
(0.68)
Return On Equity
(3.68)
The market value of Eyenovia is measured differently than its book value, which is the value of Eyenovia that is recorded on the company's balance sheet. Investors also form their own opinion of Eyenovia's value that differs from its market value or its book value, called intrinsic value, which is Eyenovia's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eyenovia's market value can be influenced by many factors that don't directly affect Eyenovia's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eyenovia's value and its price as these two are different measures arrived at by different means. Investors typically determine if Eyenovia is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eyenovia's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.